Functional assessment of genetic variants located in the promoter of SHP1 (NR0B2).

Abstract:

:Small heterodimer partner 1 (SHP1, NR0B2) is a member of the superfamily of nuclear receptors (NRs). Even if this orphan receptor, unlike other NRs, lacks the DNA-binding domain, it is capable of regulating transcription by repressing the activity of other NRs by direct protein-protein interaction. Accordingly, SHP1 is part of negative feedback loops of the transcriptional regulation of genes involved in drug metabolism and various metabolic pathways including bile acid and glucose homeostasis. Although it is known that several interacting partners of SHP1 also modulate its expression, there is little information about genetic variability of this regulatory mechanism. Our study aimed to identify genetic variants in the NR0B2 promoter region and to determine their impact on NR0B2 transcription. For this, DNA samples originating from 119 participants of the population-based cohort Study of Health in Pomerania were analyzed by Sanger sequencing revealing four genetic variants: NR0B2:c.-594T>C (rs71636795), NR0B2:c.-414G>C (newly identified), NR0B2:c.-423C>T (rs78182695), and NR0B2:c.-224delCTGA (rs145613139) localized in the 5' untranslated region of NR0B2. The impact of these variants on transactivation of the NR0B2 promoter by NRs known to be regulators of SHP1 expression (hepatocyte nuclear factor 4α, liver receptor homolog-1, and farnesoid X receptor) was assessed in a cell-based reporter gene assay, showing that transactivation by hepatocyte nuclear factor 4α and liver receptor homolog-1 was significantly decreased in the presence of the genetic variant NR0B2:c.-594T>C, even though this effect was cell specific. However, SHP1 mRNA expression in a small collection of human kidney samples was not affected by these genetic variants.

journal_name

Pharmacogenet Genomics

authors

Prestin K,Olbert M,Hussner J,Völzke H,Meyer Zu Schwabedissen HE

doi

10.1097/FPC.0000000000000310

subject

Has Abstract

pub_date

2017-11-01 00:00:00

pages

410-415

issue

11

eissn

1744-6872

issn

1744-6880

journal_volume

27

pub_type

杂志文章
  • Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men.

    abstract:OBJECTIVES:Controversy exists regarding the effects of polymorphisms in the endothelial nitric oxide synthase (eNOS) gene on nitrites/nitrates (NOx) plasma concentrations. In this study we compared the distribution of haplotypes involving three relevant eNOS polymorphisms (T-786C in the promoter region; b/a in intron 4...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01.fpc.0000167328.85163.44

    authors: Metzger IF,Souza-Costa DC,Marroni AS,Nagassaki S,Desta Z,Flockhart DA,Tanus-Santos JE

    更新日期:2005-08-01 00:00:00

  • The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.

    abstract:OBJECTIVE:Identification of biomarkers that could predict gemcitabine efficacy and toxicity is a key issue in the development of individualized therapy. The aim of our study was to evaluate the influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma (MM). METHODS:In ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32834e3572

    authors: Erčulj N,Kovač V,Hmeljak J,Franko A,Dodič-Fikfak M,Dolžan V

    更新日期:2012-01-01 00:00:00

  • Expression of ABC-type transport proteins in human platelets.

    abstract::We have identified the ATP-binding cassette (ABC) transporter ABCC4 as an active constituent of mediator-storing granules in human platelets. In addition to multidrug resistance protein 4, other ABC-type transport proteins may contribute to platelet secretory function as well as determine intended or adverse effects o...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32833997b0

    authors: Niessen J,Jedlitschky G,Grube M,Kawakami H,Kamiie J,Ohtsuki S,Schwertz H,Bien S,Starke K,Ritter C,Strobel U,Greinacher A,Terasaki T,Kroemer HK

    更新日期:2010-06-01 00:00:00

  • A novel ABCC6 haplotype is associated with azathioprine drug response in myasthenia gravis.

    abstract:OBJECTIVE:We investigated the association of single nucleotide polymorphisms (SNPs) in drug-metabolizing enzymes and transporters (DMETs) with the response to azathioprine (AZA) in patients affected by myasthenia gravis (MG) to determine possible genotype-phenotype correlations. PATIENTS AND METHODS:Genomic DNA from 1...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000257

    authors: Colleoni L,Galbardi B,Barzago C,Bonanno S,Franzi S,Frangiamore R,Camera G,Foti M,Biancolini D,Canioni E,Maggi L,Antozzi C,Mantegazza R,Bernasconi P,Kapetis D

    更新日期:2017-02-01 00:00:00

  • CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study.

    abstract:OBJECTIVE:The aim of this study was to assess whether the CYP2C9*2 and/or *3 variants might modify the risk for NSAID-related upper gastrointestinal bleeding (UGIB) in NSAID users. PATIENTS AND METHODS:We conducted a multicenter, case-control study in which cases were patients aged more than 18 years with a diagnosis ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000186

    authors: Figueiras A,Estany-Gestal A,Aguirre C,Ruiz B,Vidal X,Carvajal A,Salado I,Salgado-Barreira A,Rodella L,Moretti U,Ibáñez L,EMPHOGEN group.

    更新日期:2016-02-01 00:00:00

  • HapMap-based study of human soluble glutathione S-transferase enzymes: the role of natural selection in shaping the single nucleotide polymorphism diversity of xenobiotic-metabolizing genes.

    abstract:OBJECTIVE:Glutathione S-transferase enzymes (GSTs; EC: 2.5.1.18) constitute the principal phase II superfamily, which plays a key role in cellular detoxification. GST genes are organized in chromosomal clusters; most of these genes are polymorphic, mainly due to single nucleotide substitutions. Different studies proved...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e328349da4d

    authors: Polimanti R,Piacentini S,Fuciarelli M

    更新日期:2011-10-01 00:00:00

  • Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

    abstract:OBJECTIVES:The aim of this study was to evaluate the effect of polymorphisms affecting the clopidogrel metabolism (CYP3A4 IVS10+12G/A and CYP2C19*2) and the P2Y12 receptor (P2Y12 T744C) on modulating platelet function in acute coronary syndrome patients on dual antiplatelet treatment. BACKGROUND:Residual platelet reac...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3282f1b2be

    authors: Giusti B,Gori AM,Marcucci R,Saracini C,Sestini I,Paniccia R,Valente S,Antoniucci D,Abbate R,Gensini GF

    更新日期:2007-12-01 00:00:00

  • A novel promoter polymorphism in the human gene GNAS affects binding of transcription factor upstream stimulatory factor 1, Galphas protein expression and body weight regulation.

    abstract:OBJECTIVES:Body weight regulation is under complex control involving the central nervous system and peripheral pathways. The beta-adrenoceptor Galphas protein system plays an important role in heart rate regulation and lipid mobilization suggesting a key role for the stimulatory G protein Galphas in body weight regulat...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/FPC.0b013e3282f49964

    authors: Frey UH,Hauner H,Jöckel KH,Manthey I,Brockmeyer N,Siffert W

    更新日期:2008-02-01 00:00:00

  • Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone.

    abstract:OBJECTIVE:To examine the relationship between types and locations of mutations of the enzyme alpha-galactosidase (Gal) A in Fabry disease and the response to the pharmacological chaperone 1-deoxygalactonojirimycin (DGJ). METHODS:T cells grown from normal individuals or from patients with Fabry disease were tested for ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32830500f4

    authors: Shin SH,Kluepfel-Stahl S,Cooney AM,Kaneski CR,Quirk JM,Schiffmann R,Brady RO,Murray GJ

    更新日期:2008-09-01 00:00:00

  • The influence of human GSTZ1 gene haplotype variations on GSTZ1 expression.

    abstract:BACKGROUND/OBJECTIVES:The zeta-1 family isoform of GST biotransforms the investigational drug dichloroacetate (DCA) and certain other halogenated carboxylic acids. Haplotype variability in GSTZ1 influences the kinetics and, possibly, the toxicity of DCA. DCA metabolism correlates with expression of the GSTZ1 protein, s...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000129

    authors: Langaee TY,Zhong G,Li W,Hamadeh I,Solayman MH,McDonough CW,Stacpoole PW,James MO

    更新日期:2015-05-01 00:00:00

  • Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers.

    abstract:INTRODUCTION:Cytochrome P450 1A2 (CYP 1A2) is responsible for more than 90% of caffeine clearance. A polymorphic variant of CYP1A2 (-163C>A) (rs762551) is associated with high CYP1A2 inducibility. Both caffeine and its main metabolite, paraxanthine, may be neuroprotective. The association between caffeine intake and ri...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3282f09265

    authors: Tan EK,Chua E,Fook-Chong SM,Teo YY,Yuen Y,Tan L,Zhao Y

    更新日期:2007-11-01 00:00:00

  • GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures.

    abstract:OBJECTIVE:Several antiepileptic drugs (AEDs) are known to target the GABA(A) receptor through positive allosteric modulation of the receptors, thereby enhancing GABA(A) receptor-mediated inhibition. The large diversity of GABA(A) receptors has been reported in the central nervous system; some of these have been implica...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000000

    authors: Balan S,Sathyan S,Radha SK,Joseph V,Radhakrishnan K,Banerjee M

    更新日期:2013-11-01 00:00:00

  • Effect of folic acid intervention on the change of serum folate level in hypertensive Chinese adults: do methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms affect therapeutic responses?

    abstract:OBJECTIVES:To assess the influence of individual methylenetetrahydrofolate reductase (MTHFR) C677T and methionine synthase A2756G polymorphisms on the change of serum folate concentration in response to different dosages and durations of folic acid (FA) supplementation in hypertensive Chinese adults. METHODS:A total o...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/FPC.0b013e32834ac5e8

    authors: Qin X,Li J,Cui Y,Liu Z,Zhao Z,Ge J,Guan D,Hu J,Wang Y,Zhang F,Xu X,Wang X,Xu X,Huo Y

    更新日期:2012-06-01 00:00:00

  • A comprehensive contribution of genes for aryl hydrocarbon receptor signaling pathway to hypertension susceptibility.

    abstract:OBJECTIVE:The present study was designed to investigate whether genetic polymorphisms of the aryl hydrocarbon receptor (AHR) signaling pathway are involved in the molecular basis of essential hypertension (EH). METHODS:A total of 2160 unrelated Russian individuals comprising 1341 EH patients and 819 healthy controls w...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000261

    authors: Polonikov AV,Bushueva OY,Bulgakova IV,Freidin MB,Churnosov MI,Solodilova MA,Shvetsov YD,Ivanov VP

    更新日期:2017-02-01 00:00:00

  • Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes.

    abstract::UGT1A1 is induced by phenobarbital. We investigated whether three common UGT1A1 variants are associated with the variability in UGT1A1 inducibility. Human hepatocytes were incubated with 2 mM phenobarbital for 2 and 6 days followed by 5 microM SN-38 (1 h), a UGT1A1 probe. SN-38 glucuronidation in the cell media was me...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01.fpc.0000182784.77630.48

    authors: Ramírez J,Komoroski BJ,Mirkov S,Graber AY,Fackenthal DL,Schuetz EG,Das S,Ratain MJ,Innocenti F,Strom SC

    更新日期:2006-02-01 00:00:00

  • Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia.

    abstract::Several novel single nucleotide polymorphisms (SNPs) involved in cytarabine cytotoxicity and related to clinical outcomes have been reported recently in a series of 232 pediatric patients with acute myeloid leukemia (AML). We report the first adult AML cohort in which the influence of these SNPs in cytarabine efficacy...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000286

    authors: Megías-Vericat JE,Montesinos P,Herrero MJ,Moscardó F,Bosó V,Martínez-Cuadrón D,Poveda JL,Sanz MÁ,Aliño SF

    更新日期:2017-07-01 00:00:00

  • Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.

    abstract:BACKGROUND:For prevention of joint destruction in rheumatoid arthritis, optimal management of therapy with disease-modifying antirheumatic drugs is essential. Pharmacogenomic evidence, if reliable, may be incorporated in the treatment of rheumatoid arthritis to achieve a more efficient activity control with minimized a...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01.fpc.0000236326.80809.b1

    authors: Taniguchi A,Urano W,Tanaka E,Furihata S,Kamitsuji S,Inoue E,Yamanaka M,Yamanaka H,Kamatani N

    更新日期:2007-06-01 00:00:00

  • Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding.

    abstract:OBJECTIVES:To analyze whether gene variants leading to impaired drug metabolism are related with acute gastrointestinal bleeding after nonsteroidal anti-inflammatory drugs (NSAID) use. METHODS:Common CYP2C8 and CYP2C9 polymorphisms were studied in a cross-sectional study, involving 134 NSAID-related bleeding patients ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3282f305a9

    authors: Blanco G,Martínez C,Ladero JM,Garcia-Martin E,Taxonera C,Gamito FG,Diaz-Rubio M,Agundez JA

    更新日期:2008-01-01 00:00:00

  • Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients.

    abstract:OBJECTIVE:Compared with genetic factors, drug interactions are largely unexplored in pharmacogenetic studies. This study sought to systematically investigate the effects of VKORC1, STX4A, CYP2C9, CYP4F2, CYP3A4, and GGCX gene polymorphisms and interacting drugs on warfarin maintenance dose. METHODS:A retrospective stu...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32834f45f9

    authors: Zhong SL,Yu XY,Liu Y,Xu D,Mai LP,Tan HH,Lin QX,Yang M,Lin SG

    更新日期:2012-03-01 00:00:00

  • Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.

    abstract:BACKGROUND/AIM:Cytochrome P450 oxidoreductase (POR) is required for drug metabolism by all microsomal cytochrome P450 (CYP) enzymes. The aim of this study was to investigate whether single-nucleotide polymorphisms in the POR gene were correlated with interindividual variations in CYP2B6 activity, as measured by bupropi...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000190

    authors: Lv J,Hu L,Zhuo W,Zhang C,Zhou H,Fan L

    更新日期:2016-02-01 00:00:00

  • Three haplotypes associated with CYP2A6 phenotypes in Caucasians.

    abstract::The human cytochrome P450 2A6 (CYP2A6) enzyme metabolizes several xenobiotic compounds of clinical or toxicological importance. We aimed to identify genetic variants and major CYP2A6 haplotypes associated with CYP2A6 phenotypic variation. CYP2A6 mRNA level, protein level, activity and haplotypes were determined in Cau...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01.fpc.0000171517.22258.f1

    authors: Haberl M,Anwald B,Klein K,Weil R,Fuss C,Gepdiremen A,Zanger UM,Meyer UA,Wojnowski L

    更新日期:2005-09-01 00:00:00

  • Application of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFbetaR therapy.

    abstract:OBJECTIVES:The development of targeted drugs would greatly benefit from the simultaneous identification of biomarkers to determine the aspects of bioactivity, drug safety and efficacy, particularly when affecting receptor-signaling pathways. However, the establishment of appropriate systems to monitor drug-induced even...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e328335731c

    authors: Classen S,Muth C,Debey-Pascher S,Eggle D,Beyer M,Mallmann MR,Rudlowski C,Zander T,Pölcher M,Kuhn W,Lahn M,Schultze JL,Staratschek-Jox A

    更新日期:2010-03-01 00:00:00

  • Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.

    abstract:OBJECTIVE:Exemestane is a third-generation aromatase inhibitor used in the treatment of breast cancer in postmenopausal women. Reduction to form 17-dihydroexemestane and subsequent glucuronidation to exemestane-17-O-glucuronide is a major pathway for exemestane metabolism. The goal of this study was to analyze 17-dihyd...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32833b04af

    authors: Sun D,Chen G,Dellinger RW,Sharma AK,Lazarus P

    更新日期:2010-10-01 00:00:00

  • Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.

    abstract:OBJECTIVES:Nine different functional UGT1A enzymes are generated from a single UGT1A gene by alternative splicing, with each enzyme having a unique exon 1. SN-38, the active metabolite of the anticancer agent irinotecan, is metabolized by both UGT1A1 and UGT1A9. We aim to characterize the UGT1A9-UGT1A1 haplotypes in As...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01213011-200505000-00004

    authors: Innocenti F,Liu W,Chen P,Desai AA,Das S,Ratain MJ

    更新日期:2005-05-01 00:00:00

  • High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.

    abstract:INTRODUCTION:Efavirenz is primarily metabolized by CYP2B6, with a minor contribution from CYP1A2, CYP2A6, CYP3A4 and CYP3A5. Genetic variability in these genes contributes towards differences in plasma efavirenz concentration, which ultimately leads to either development of adverse drug events or emergence of virus res...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e328363176f

    authors: Swart M,Skelton M,Ren Y,Smith P,Takuva S,Dandara C

    更新日期:2013-08-01 00:00:00

  • Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype.

    abstract::Genotyping N-acetyltransferase 2 (NAT2) is of high relevance for individualized dosing of antituberculosis drugs and bladder cancer epidemiology. In this study we compared a recently published tagging single nucleotide polymorphism (SNP) (rs1495741) to the conventional 7-SNP genotype (G191A, C282T, T341C, C481T, G590A...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3283493a23

    authors: Selinski S,Blaszkewicz M,Lehmann ML,Ovsiannikov D,Moormann O,Guballa C,Kress A,Truss MC,Gerullis H,Otto T,Barski D,Niegisch G,Albers P,Frees S,Brenner W,Thüroff JW,Angeli-Greaves M,Seidel T,Roth G,Dietrich H,Ebbin

    更新日期:2011-10-01 00:00:00

  • Association of GSTM1 null polymorphism with isosorbide-5-mononitrate cardiovascular response and involvement of CGRP in healthy Chinese male volunteers.

    abstract:OBJECTIVES:To determine whether functional polymorphisms of glutathione S-transferase μ type 1 (GSTM1) and aldehyde dehydrogenase-2 (ALDH2) affect the isosorbide 5-mononitrate (IS-5-MN) response, and the role of the calcitonin gene-related peptide (CGRP) in IS-5-MN response in healthy volunteers. METHODS:A two-phase, ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e328343ea0a

    authors: Guo R,Chen L,Li L,Guo X,Sun J,Xiong XM,Cheng ZN,Li YJ,Chen XP

    更新日期:2011-03-01 00:00:00

  • Variants in COMT and spontaneous smoking cessation: retrospective cohort analysis of 925 cessation events.

    abstract::Genome-wide studies have identified single nucleotide polymorphisms associated with smoking behaviour and nicotine dependence. Less is known about genetic determinants of smoking cessation, but rs4680 in COMT has recently been shown to explain a substantial proportion of the variation in cessation in the general popul...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32832fabf3

    authors: Breitling LP,Dahmen N,Illig T,Rujescu D,Nitz B,Raum E,Winterer G,Rothenbacher D,Brenner H

    更新日期:2009-08-01 00:00:00

  • Genetic variation-optimized treatment benefit of angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: a 12-year follow-up study.

    abstract:OBJECTIVES:The objective of this study was to examine the relationship between renin-angiotensin system genotypes and the pharmacogenetics of angiotensin-converting enzyme (ACE) inhibitors in Chinese patients with coronary artery disease (CAD). METHODS:Patients with angiographic CAD were recruited from 1995 to 2003. T...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32835a0ffa

    authors: Lee JK,Wu CK,Tsai CT,Lin LY,Lin JW,Chien KL,Hwang JJ,Lin CL,Tseng CD,Chiang FT

    更新日期:2013-04-01 00:00:00

  • Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans.

    abstract::Two recent screens for copy-number variations in the entire human genome found 12.4 gene copy number variations per person, including 2.5% of individuals with gains between 7q21.1 and 7q22.1, the chromosomal location of CYP3A4. CYP3A4 is involved in the metabolism of approximately 50% of all drugs, including many canc...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01.fpc.0000194421.35641.70

    authors: Lamba JK,Chen X,Lan LB,Kim JW,Wei Wang X,Relling MV,Kazuto Y,Watkins PB,Strom S,Sun D,Schuetz JD,Schuetz EG

    更新日期:2006-06-01 00:00:00